Laboratory and clinical studies on latamoxef in the field of obstetrics and gynecology
Takase, Z.; Shirafuji, H.; Matsuda, S.; Tanno, M.; Kashiwakura, T.; Cho, N.; Fukunaga, K.; Kunii, K.; Hogaki, M.; Muronosono, E.; Matsumoto, Y.; Tabei, T.; Hayashi, S.; Nakamura, H.; Seki, K.; Fukuda, T.; Aoyama, S.; Kurasawa, S.; Ninomiya, K.; Hiraoka, O.; Nakai, T.; Shimizu, H.; Sugimoto, O.; Kamiyoshi, S.; Watanabe, K.; Fujimoto, A.; Doi, S.; Jujii, K.; Yamada, F.; Ozawa, M.; Shimizu, T.; Risai, T.; Morimoto, N.; Kobayashi, H.; Kondo, I.; Saita, K.; Ibaragi, K.; Kamigawara, Y.; Sawaragi, I.;
Japanese Journal of Antibiotics 36(1): 1-15
1983
ISSN/ISBN: 0368-2781 PMID: 6221127 Document Number: 213794
Latamoxef (LMOX) is a new antibiotic synthesized by Shionogi Research Laboratory. Chemically LMOX is especially unique with a sulfur atom replacing the oxygen atom in the 1 position of the conventional cephalosporin nucleus, and in addition, this antibiotic has a cephamycin-like structure. The antibacterial activity of LMOX shows high potency against Gram-negative bacteria, but tends to be weak against Gram-positive bacteria. The tissue levels of LMOX in humans after intravenous injection of 1 g were examined. The levels in uterine and adnexa uteri tissue at 1 hour after administration were 25.4 and 27.4 micrograms/g respectively. LMOX was administered to 147 cases in infections of obstetric and gynecological field. The clinical effect according to disease was 94.6% for intrauterine infections, 95.0% for adnexitis, 87.0% intrapelvic infections, and 100% for external genital organ infections, making a total of 92.5%. The rate of occurrence of side effects or abnormal laboratory findings was similar to or slightly less than that seen with other beta-lactam antibiotics.